Filing Details
- Accession Number:
- 0001144204-15-000635
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-01-05 21:00:49
- Reporting Period:
- 2015-01-01
- Filing Date:
- 2015-01-05
- Accepted Time:
- 2015-01-05 21:00:49
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1270073 | Intercept Pharmaceuticals Inc | ICPT | Pharmaceutical Preparations (2834) | 223868459 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1353128 | Gayle Barbara Duncan | C/O Intercept Pharmaceuticals, Inc. 450 W. 15Th Street, Suite 505 New York NY 10011 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-01-01 | 1,298 | $0.00 | 17,405 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2015-01-02 | 1,000 | $31.90 | 18,405 | No | 4 | M | Direct | |
Common Stock | Disposition | 2015-01-02 | 500 | $154.45 | 17,905 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-01-02 | 500 | $158.35 | 17,405 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted Stock Units | Disposition | 2015-01-01 | 1,298 | $0.00 | 1,298 | $0.00 |
Common Stock | Options to Purchase Common Stock | Disposition | 2015-01-02 | 1,000 | $0.00 | 1,000 | $31.90 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
5,192 | No | 4 | M | Direct | ||
14,875 | 2023-05-07 | No | 4 | M | Direct |
Footnotes
- The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 17, 2014.
- Conversion of restricted stock units ("RSUs") to shares of common stock on a one-to-one basis.
- On November 16, 2012, the reporting person was granted 20,769 RSUs. The RSUs reported as having been disposed and the corresponding shares reported as having been acquired, representing 6.25% of the shares underlying the RSUs, became vested on January 1, 2015, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remainder of the shares underlying the RSUs will vest pro rata on a quarterly basis from April 1, 2015 through January 1, 2016, subject to the terms and conditions of the award and the 2012 Plan.
- This option to purchase common stock was originally granted to the reporting person on May 7, 2013 (original amount: 22,500 shares). 25% of the shares of common stock underlying this option vested on January 1, 2014, subject to the terms and conditions of the award and the 2012 Plan. The remainder of the shares of common stock underlying this option will vest pro rata on a monthly basis after the initial vesting date through January 1, 2017 (representing the vesting of approximately 2.0833% of the shares of common stock initially underlying these options on each such vesting date), subject to the terms and conditions of the award and the 2012 Plan.